Palliative chirurgische Therapieoptionen beim kastrationsresistenten Prostatakarzinom
Abstract
If prostate cancer recurs after primary treatment, deprivation therapy with LHRH analogues or antagonists is the treatment of choice in men with metastatic prostate cancer. However, this treatment only achieves palliative results. Median time to progression ranges between 11 and 78 months. After the introduction of Docetaxel as a first-line treatment in castration-resistant prostate cancer (CRPCA) and cabazitaxel as a second-line chemotherapy,...
Paper Details
Title
Palliative chirurgische Therapieoptionen beim kastrationsresistenten Prostatakarzinom
Published Date
Sep 1, 2018
Journal
Volume
49
Issue
05
Pages
405 - 411
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History